Paul G. Auwaerter, M.D., Kathryn Dzintars, Pharm.D., BCPS



The FDA fully approved (2023) drug after initial Emergency Use Authorization (EUA) for the emergency use of Paxlovid (nirmatrelvir/ritonavir) for the treatment of mild-to-moderate COVID-19 disease in adults and children ≥ 12 years of age who are at high risk for progressing to severe COVID-19 illness, including hospitalization and death.

  • Risk factors for severe disease include diabetes, overweight (BMI >25), chronic lung disease, chronic kidney disease, current smoker, immunosuppressive disease or immunosuppressive treatment, cardiovascular disease, hypertension, sickle cell disease, neurodevelopmental disorders, active cancer, and patients >60 years of age.
  • The FDA removed an earlier requirement for a positive SARS-CoV-2 test from the EUA in February 2023.

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: November 12, 2023